Hofseth BioCare ASA (HBC.OL)
NOK 1.41
(-23.37%)
NOK 1.41
(-23.37%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 82.54 Million NOK | -29.16% |
| 2022 | 116.52 Million NOK | 28.31% |
| 2021 | 90.81 Million NOK | 23.89% |
| 2020 | 73.3 Million NOK | 115.68% |
| 2019 | 33.98 Million NOK | 15.59% |
| 2018 | 29.4 Million NOK | 74.41% |
| 2017 | 16.85 Million NOK | 8.14% |
| 2016 | 15.58 Million NOK | -69.32% |
| 2015 | 50.81 Million NOK | -0.44% |
| 2014 | 51.04 Million NOK | 97.62% |
| 2013 | 25.82 Million NOK | 323.29% |
| 2012 | 6.1 Million NOK | 1339.15% |
| 2011 | 424 Thousand NOK | 0.0% |
| 2010 | - NOK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 83.71 Million NOK | 1.42% |
| 2024 Q2 | 72.45 Million NOK | -13.46% |
| 2023 Q3 | 101.56 Million NOK | -7.78% |
| 2023 Q4 | 82.54 Million NOK | -18.73% |
| 2023 FY | 82.54 Million NOK | -29.16% |
| 2023 Q1 | 108.75 Million NOK | -6.67% |
| 2023 Q2 | 110.13 Million NOK | 1.27% |
| 2022 Q1 | 92.71 Million NOK | 2.09% |
| 2022 FY | 116.52 Million NOK | 28.31% |
| 2022 Q4 | 116.52 Million NOK | 6.98% |
| 2022 Q3 | 108.92 Million NOK | 6.9% |
| 2022 Q2 | 101.89 Million NOK | 9.91% |
| 2021 Q2 | 87.23 Million NOK | 2.29% |
| 2021 FY | 90.81 Million NOK | 23.89% |
| 2021 Q1 | 85.28 Million NOK | 16.35% |
| 2021 Q3 | 88.97 Million NOK | 1.99% |
| 2021 Q4 | 90.81 Million NOK | 2.06% |
| 2020 Q2 | 54.88 Million NOK | 20.21% |
| 2020 Q1 | 45.65 Million NOK | 34.33% |
| 2020 FY | 73.3 Million NOK | 115.68% |
| 2020 Q3 | 64.47 Million NOK | 17.48% |
| 2020 Q4 | 73.3 Million NOK | 13.68% |
| 2019 Q3 | 31.98 Million NOK | -24.7% |
| 2019 FY | 33.98 Million NOK | 15.59% |
| 2019 Q1 | 35.84 Million NOK | 21.93% |
| 2019 Q4 | 33.98 Million NOK | 6.25% |
| 2019 Q2 | 42.47 Million NOK | 18.49% |
| 2018 Q1 | 20.57 Million NOK | 22.07% |
| 2018 FY | 29.4 Million NOK | 74.41% |
| 2018 Q4 | 29.4 Million NOK | 20.48% |
| 2018 Q2 | 23.75 Million NOK | 15.42% |
| 2018 Q3 | 24.4 Million NOK | 2.74% |
| 2017 Q2 | 27.07 Million NOK | 37.5% |
| 2017 FY | 16.85 Million NOK | 8.14% |
| 2017 Q4 | 16.85 Million NOK | -14.74% |
| 2017 Q1 | 19.69 Million NOK | 26.31% |
| 2017 Q3 | 19.77 Million NOK | -26.97% |
| 2016 Q4 | 15.58 Million NOK | -14.68% |
| 2016 FY | 15.58 Million NOK | -69.32% |
| 2016 Q1 | 45.82 Million NOK | -9.83% |
| 2016 Q2 | 29.76 Million NOK | -35.05% |
| 2016 Q3 | 18.27 Million NOK | -38.61% |
| 2015 Q1 | 48.85 Million NOK | -4.28% |
| 2015 FY | 50.81 Million NOK | -0.44% |
| 2015 Q4 | 50.81 Million NOK | -13.77% |
| 2015 Q3 | 58.93 Million NOK | 21.99% |
| 2015 Q2 | 48.31 Million NOK | -1.12% |
| 2014 Q2 | 47.8 Million NOK | 30.53% |
| 2014 FY | 51.04 Million NOK | 97.62% |
| 2014 Q1 | 36.62 Million NOK | 41.78% |
| 2014 Q4 | 51.04 Million NOK | -15.3% |
| 2014 Q3 | 60.26 Million NOK | 26.08% |
| 2013 Q4 | 25.82 Million NOK | 16.2% |
| 2013 Q2 | 16.69 Million NOK | 156.53% |
| 2013 Q1 | 6.5 Million NOK | 6.62% |
| 2013 FY | 25.82 Million NOK | 323.29% |
| 2013 Q3 | 22.22 Million NOK | 33.19% |
| 2012 Q3 | 2.37 Million NOK | -38.36% |
| 2012 Q1 | 381 Thousand NOK | -10.14% |
| 2012 FY | 6.1 Million NOK | 1339.15% |
| 2012 Q2 | 3.85 Million NOK | 910.5% |
| 2012 Q4 | 6.1 Million NOK | 157.14% |
| 2011 Q4 | 424 Thousand NOK | 0.0% |
| 2011 Q3 | - NOK | 0.0% |
| 2011 FY | 424 Thousand NOK | 0.0% |
| 2010 FY | - NOK | 0.0% |
| 2010 Q4 | - NOK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Arctic Bioscience AS | 32.79 Million NOK | -151.7% |
| Aqua Bio Technology ASA | 5.69 Million NOK | -1350.168% |
| ArcticZymes Technologies ASA | 12.87 Million NOK | -541.203% |
| BerGenBio ASA | 7.84 Million NOK | -952.563% |
| PCI Biotech Holding ASA | 1000.00 NOK | -8254100.0% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | 1.00 NOK | -8254199900.0% |